Sirona Biochem

102 articles about Sirona Biochem

• Sirona Biochem Corporate Update - July 13, 2023

  7/13/2023

  Sirona Biochem Corp . (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“ Sirona ”) provides the following update: Dear shareholders, We are pleased to provide an update on the progress we have made over the last months: Corporate Strategic Planning One of our communicated objectives in 2022 and the first half of 2023 was to conduct a thorough strategic review of the company.

• Sirona Biochem Advances Antiviral Research with New Compound Candidates for Testing at the ICGEB

  6/28/2023

  Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (" Sirona ") is excited to announce the development of a promising new set of potential antiviral compounds which will undergo testing at the renowned International Centre for Genetic Engineering and Biotechnology ( ICGEB ).

• Sirona Biochem Engages Atheln Inc. to Strengthen Business Development Initiatives

  5/25/2023

  Sirona Biochem Corp. is pleased to announce it has contracted Atheln Inc., a leading US consulting firm, to bolster and facilitate Sirona's business activities.

• Sirona Biochem: Investing News Network Interview with CSO, Dr. Geraldine Deliencourt-GodefroyAn In-Depth Look at Anti-Aging Compound TFC-1326

  5/11/2023

  Sirona Biochem Corp. is pleased to announce that the Investing News Network has published an exclusive video interview with Dr. Geraldine Deliencourt-Godefroy, the Chief Scientific Officer of Sirona.

• Sirona Biochem Announces Close of Oversubscribed Debenture Financing

  4/20/2023

  Sirona Biochem Corp. announced that it has closed an oversubscribed, non-brokered convertible debenture for gross proceeds of $1,563,600.

• Sirona Biochem Announces Debenture Financing

  3/23/2023

  Sirona Biochem Corp. is pleased to announce a non-brokered private placement offering of unsecured, convertible debentures.

• Sirona Biochem Receives Antiviral Testing Results

  2/27/2023

  Sirona Biochem Corp. is pleased to announce it has received results from its research collaboration with the International Centre for Genetic Engineering and Biotechnology to advance Sirona’s antiviral library of compounds.

• Sirona Biochem Announces the Termination of Supply Agreement with Rodan + Fields

  1/16/2023

  Sirona Biochem Corp. announces the termination of the Rodan + Fields agreement for supply and use of TFC-1067 in commercial formulations.

• Sirona Biochem Announces 2022 Annual Meeting Results

  12/30/2022

  Sirona Biochem Corp. announces the voting results from its Annual General Meeting of Shareholders, held in Vancouver, British Columbia on December 30, 2022.

• Sirona Biochem Signs Research Collaboration Agreement with International Centre for Genetic Engineering and Biotechnology

  11/10/2022

  Sirona Biochem Corp. is pleased to announce it has entered into a research collaboration with the International Centre for Genetic Engineering and Biotechnology to advance Sirona’s antiviral library of compounds.

• Sirona Biochem Issues Corporate Update - September 29, 2022

  9/29/2022

  Sirona Biochem Corp. announces the release of a corporate update which highlights the company’s recent team meeting in France, the current pipeline, and the latest deal structure.

• Former Bayer Senior Executive Joins Sirona Biochem Advisory Board

  6/20/2022

  Sirona Biochem Corp. is pleased to announce that Dr. Wolfgang Bieber will join Sirona Biochem’s Advisory Board and act as a consultant to the Board of Directors with immediate effect.

• Sirona Biochem Initiates Significant Corporate Changes

  6/15/2022

  Now that Sirona Biochem has closed an exclusive global licencing agreement with Allergan Aesthetics, the next steps for sustainable and rapid growth of the company are initiated.

• Sirona Biochem Announces Exclusive Global Licensing Agreement with Allergan AestheticsLicenses Revolutionary Skin Care Compound TFC-1067

  6/13/2022

  Sirona Biochem Corp. is pleased to announce it has entered into a global exclusive licensing agreement with Allergan Aesthetics, an AbbVie company, pursuant to which Allergan Aesthetics will develop and commercialize topical skin care treatments based on active ingredients derived from certain of Sirona’s patents for TFC-1067 and related family of compounds.

• Sirona Biochem Subsidiary, TFChem, Awarded Financing in Partnership with French Government

  3/9/2022

  Sirona Biochem Corp. is pleased to announce that its wholly owned subsidiary TFChem, has been awarded financing to develop an advanced chemistry process that could improve the manufacturing of active ingredients.

• Sirona Biochem Renews Agreement with CURE Intelligence for Marketing and Communications Support

  1/18/2022

  Sirona Biochem Corp. is pleased to announce that it has renewed an agreement with Luxembourg-based analytics and marketing specialist CURE Intelligence for marketing intelligence services and communications support.

• Sirona Biochem Sponsors Fluorine Chemistry Symposium, Normandy, France

  1/12/2022

  Sirona Biochem Corp. is pleased to announce sponsorship of the French Fluorine Chemistry Symposium which will take place in Normandy, France, May 16-19, 2022 in Forges-les-Eaux.

• Sirona Biochem CEO Quarterly Update

  1/4/2022

  Individual countries have regulatory requirements which can differ from the rest of the world. The full library of compounds will provide a path to navigate various regions and offer partnerships beyond just the initial compound.

• Sirona Biochem Announces Development of an Anti-Wrinkle Treatment and Update From J.P. Morgan Healthcare Conference

  1/31/2018

  The compound, LIP-01, was discovered to have a novel mechanism of action and will enter pre-clinical studies as a plumping/smoothing ingredient for aging skin.

• Sirona Biochem Announces Receipt of $500,000 US Milestone Payment

  1/29/2018

  The Company now awaits the CFDA approval of the IND filing, which will lead to a clinical trial of Sirona's SGLT2 inhibitor for diabetes.